colistin resistance (mcr genes), screening for isolates with phenotypic colistin resistance has become clinically and epidemiologically relevant. However, antimicrobial susceptibility testing (AST) of colistin is associated with several technical challenges. Disk diffusion does not work because of poor diffusion of the large colistin molecule, Etest has been reported to underestimate minimum inhibitory concentration (MIC) values, and most clinical microbiology laboratories lack the capacity to perform broth microdilution (BMD). In this study, we compared the Etest method with the reference BMD method described by the Clinical and Laboratory Standards Institute (CLSI) for determining colistin MICs among Enterobacteriaceae. A total of 114 isolates of Enterobacteriaceae (51 carbapenem-resistant [CRE] and 63 carbapenem-susceptible [CSE]) were selected for colistin AST. One CRE isolate and 13 CSE isolates harbored a mcr gene. BMD testing was performed according to CLSI guidelines using a frozen reference panel with colistin concentrations ranging from 0.25 to 8 µg/mL. The Etest (BioMérieux, Durham, NC) method was performed on Mueller-Hinton agar (BBL, Becton Dickinson, Sparks, MD) according to the manufacturer's instructions. Interpretive criteria based on CLSI epidemiological cutoff values (non-wild-type ≥4 µg/mL; wild-type ≤2 µg/mL) were used to define resistance and susceptibility to colistin, respectively. By BMD, colistin MICs ranged from ≤0.25 to >8 µg/ mL and 27% were determined to be colistin-resistant. The categorical agreement between Etest and BMD was 92%. All 14 mcr-positive isolates were categorized as colistin-resistant by BMD, while Etest classified 13/14 as resistant. In conclusion, clinical microbiology laboratories lacking capacity to perform BMD could implement the Etest method with BBL Mueller-Hinton agar for epidemiological purposes to help identify candidate isolates for mcr screening. To determine whether colistin can be used clinically, BMD would still be required.
Association Between Biofilm Production and Antibiotic Resistance in Acinetobacter Clinical Isolates
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Objectives: We aimed to determine the association between biofilm production and antibiotic resistance in Acinetobacter clinical isolates. Methods: A total of 100 clinical isolates of Acinetobacter were collected from clinical settings in Cairo, Egypt. The antibiogram of Acinetobacter isolates showed high resistance percentage to the most tested antibiotics by Vitek2 automated system. The ability of these isolates to produce biofilm was determined by different methods, with the tissue culture plate method (microtiter plat method) regarded as the gold standard method as it is the most accurate; it has determined 24 isolates as high producers, 34 isolates as moderate producers, and 42 isolates as weak producers of biofilm. Results: Testing of antibacterial activities of eight essential oils against the 12 selected biofilm producing Acinetobacter isolates revealed that only four essential oils-cinnamon, clove, thyme, and eucalyptus-exhibited promising antibacterial activity against the test isolates, so we tested these selected oils against biofilm production. Out of the four oils, only cinnamon has shown promising antibiofilm activity against the test isolates. GC/MS analysis of the most active essential oil revealed that cinnamaldehyde in cinnamon was the main component in the oil. Testing of antibiofilm activities of the major component (ie, cinnamaldehyde) of the most active oil (ie, cinnamon oil) against the selected biofilm producing Acinetobacter isolates demonstrated a lower antibiofilm activity of cinnamaldehyde against the tested isolates, compared to cinnamon oil. Conclusion: Our data suggest that essential oils can represent promising natural components suitable for use as antibacterial and antibiofilm agents with a particular interest for the pharmaceutical industry as they are inexpensive compounds.
